Ligence Heart vs Lung Density Analysis
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 65/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Ligence Heart is an AI-powered platform specifically designed for the automated analysis and reporting of 2D transthoracic echocardiography, focusing on various cardiac conditions. In contrast, Lung Density Analysis is an AI-driven software that provides quantitative analysis and 3D visualization of lung conditions from CT scans, primarily for pulmonary diseases. While both are FDA-cleared AI tools for medical imaging, they target different organ systems and utilize distinct imaging modalities, making them complementary rather than directly competitive.
Choose Ligence Heart if…
Choose Ligence Heart if your cardiology department aims to significantly enhance the efficiency and accuracy of 2D transthoracic echocardiography analysis. This tool is ideal for automating measurements, classifying views, and generating comprehensive reports for conditions like heart failure and valvular diseases, thereby standardizing diagnostic workflows.
View Ligence Heart →Choose Lung Density Analysis if…
Choose IMBIO Lung Density Analysis if your radiology or pulmonology practice requires advanced quantitative assessment and 3D visualization of lung conditions from CT scans. This solution is particularly well-suited for diagnosing and managing diseases such as COPD and emphysema, offering automated workflows and detailed reports for personalized patient care, even with low-dose CT scans.
View Lung Density Analysis →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Ligence Heart | Lung Density Analysis |
|---|---|---|
| Pricing | Contact-for-pricing | Unknown |
| Deployment | Cloud-based; on-premise; hybrid | Unknown |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Ligence Heart | Lung Density Analysis |
|---|---|---|
| Tool Name | Ligence Heart | Lung Density Analysis |
| Company | Ligence | IMBIO |
| Primary Medical Imaging Modality | 2D transthoracic echocardiography | CT scans |
| Target Medical Conditions/Focus | Heart failure, cardiomyopathy, pulmonary hypertension, valvular heart diseases | COPD, emphysema, asthma, BOS, lung cancer screening |
| Key Automated Analysis Capabilities | Automated recognition of echocardiography imaging data, view classification, heart phase prediction, measurement calculation, report generation, Area, Distance, Doppler, Volume quantification, strain, Spectral and Tissue Doppler measurements | Automated detection, visualization, and quantification of emphysema; quantitative analysis and 3D visualization; mapping of normal lung, air-trapping, and emphysema; advanced density analysis |
| Integration with Existing Systems | PACS, EHR, RIS | PACS, AI marketplace/distribution platforms (as part of deployment) |
Videos
Demos, reviews, and walkthroughs featuring Ligence Heart and Lung Density Analysis.
Loading videos…
Videos need JavaScript to load. Search YouTube directly →
Frequently Asked Questions
Ligence Heart is an AI-powered platform designed for cardiologists and sonographers, automating the analysis and reporting of 2D transthoracic echocardiography to enhance diagnostic efficiency and accuracy for various heart conditions. IMBIO's Lung Density Analysis is an AI-driven medical imaging software for pulmonologists and radiologists, providing quantitative analysis and 3D visualization of lung conditions from CT scans, aiding in the diagnosis and management of diseases like COPD and emphysema.
Ligence Heart specializes in the automated analysis of 2D transthoracic echocardiography imaging data. In contrast, IMBIO's Lung Density Analysis is designed to provide quantitative analysis and 3D visualization of lung conditions from CT scans.
Ligence Heart offers disease recognition for conditions such as heart failure, cardiomyopathy, pulmonary hypertension, and valvular heart diseases through automated echocardiography analysis. IMBIO's Lung Density Analysis focuses on the automated detection, visualization, and quantification of emphysema, and provides advanced density analysis for COPD, Asthma, and Bronchiolitis Obliterans Syndrome (BOS).
Ligence Heart offers integration with existing systems such as PACS, EHR, and RIS for seamless workflow. IMBIO's Lung Density Analysis also supports integration into PACS, AI marketplace/distribution platforms, and can be deployed as a stand-alone web-based solution or locally virtualized.
Ligence Heart automates the generation of reports based on calculated measurements and disease recognition from echocardiography data. IMBIO's Lung Density Analysis provides detailed quantitative reports, including a patient-centered LungMapu2122 report for smoking cessation counseling, and advanced reports with coronal, axial, sagittal visuals and bar charts for lung conditions.